BR112018071023A2 - combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose - Google Patents
combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitoseInfo
- Publication number
- BR112018071023A2 BR112018071023A2 BR112018071023A BR112018071023A BR112018071023A2 BR 112018071023 A2 BR112018071023 A2 BR 112018071023A2 BR 112018071023 A BR112018071023 A BR 112018071023A BR 112018071023 A BR112018071023 A BR 112018071023A BR 112018071023 A2 BR112018071023 A2 BR 112018071023A2
- Authority
- BR
- Brazil
- Prior art keywords
- combinations
- mitosis inhibitors
- treating neoplasms
- cell targeting
- inactive cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000011278 mitosis Effects 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 229940121849 Mitotic inhibitor Drugs 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323583P | 2016-04-15 | 2016-04-15 | |
| PCT/US2017/027734 WO2017181087A1 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071023A2 true BR112018071023A2 (pt) | 2019-02-05 |
Family
ID=60039311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071023A BR112018071023A2 (pt) | 2016-04-15 | 2017-04-14 | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10314843B2 (OSRAM) |
| EP (1) | EP3443351A4 (OSRAM) |
| JP (1) | JP7278776B2 (OSRAM) |
| KR (2) | KR20230020560A (OSRAM) |
| CN (1) | CN109313197A (OSRAM) |
| AU (2) | AU2017248807A1 (OSRAM) |
| BR (1) | BR112018071023A2 (OSRAM) |
| CA (1) | CA3020978A1 (OSRAM) |
| IL (2) | IL292475A (OSRAM) |
| MX (2) | MX2018012508A (OSRAM) |
| WO (1) | WO2017181087A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562176A (zh) | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150104T1 (xx) * | 2009-09-11 | 2015-03-13 | Amgen, Inc. | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-thienil)-1-ftalazinamin za primjenu u tretmanu kancera rezistentnog na antimitotiäśke agense |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| PL2744797T3 (pl) * | 2011-08-19 | 2016-01-29 | Diaxonhit | Inhibitory dyrk1 i ich zastosowanie |
| FR2993317B1 (fr) | 2012-07-16 | 2014-08-15 | Snecma | Carter de turbomachine dans un materiau composite et procede de fabrication associe |
| US20150292032A1 (en) * | 2012-10-10 | 2015-10-15 | Felicitex Therapeutics, Inc. | Treatment of cancer by targeting quiescent cancer cells |
| EP3007692A1 (en) * | 2013-06-11 | 2016-04-20 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| CA2854542A1 (en) * | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| US9566280B2 (en) * | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| PE20170127A1 (es) * | 2014-03-20 | 2017-03-30 | Samumed Llc | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas |
| US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| CN108135871B (zh) * | 2015-07-23 | 2022-11-04 | 博蔚医药生物科技股份有限公司 | 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物 |
| CN109562176A (zh) | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
-
2017
- 2017-04-14 BR BR112018071023A patent/BR112018071023A2/pt not_active Application Discontinuation
- 2017-04-14 IL IL292475A patent/IL292475A/en unknown
- 2017-04-14 US US15/488,143 patent/US10314843B2/en active Active
- 2017-04-14 WO PCT/US2017/027734 patent/WO2017181087A1/en not_active Ceased
- 2017-04-14 CN CN201780037724.5A patent/CN109313197A/zh active Pending
- 2017-04-14 CA CA3020978A patent/CA3020978A1/en active Pending
- 2017-04-14 JP JP2018554360A patent/JP7278776B2/ja active Active
- 2017-04-14 EP EP17783296.1A patent/EP3443351A4/en not_active Withdrawn
- 2017-04-14 KR KR1020237002817A patent/KR20230020560A/ko not_active Ceased
- 2017-04-14 AU AU2017248807A patent/AU2017248807A1/en not_active Abandoned
- 2017-04-14 MX MX2018012508A patent/MX2018012508A/es unknown
- 2017-04-14 KR KR1020187033030A patent/KR102494172B1/ko active Active
-
2018
- 2018-10-11 IL IL262325A patent/IL262325B/en unknown
- 2018-10-12 MX MX2022012146A patent/MX2022012146A/es unknown
-
2019
- 2019-06-10 US US16/436,305 patent/US20190290651A1/en not_active Abandoned
-
2021
- 2021-12-21 US US17/558,204 patent/US20220110941A1/en not_active Abandoned
-
2023
- 2023-08-08 AU AU2023214240A patent/AU2023214240A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017248807A1 (en) | 2018-10-25 |
| CA3020978A1 (en) | 2017-10-19 |
| US20190290651A1 (en) | 2019-09-26 |
| KR102494172B1 (ko) | 2023-02-02 |
| IL292475A (en) | 2022-06-01 |
| AU2023214240A1 (en) | 2023-08-24 |
| MX2022012146A (es) | 2022-10-21 |
| US20220110941A1 (en) | 2022-04-14 |
| MX2018012508A (es) | 2019-07-08 |
| WO2017181087A1 (en) | 2017-10-19 |
| CN109313197A (zh) | 2019-02-05 |
| IL262325B (en) | 2022-06-01 |
| KR20230020560A (ko) | 2023-02-10 |
| US20170296542A1 (en) | 2017-10-19 |
| KR20180130575A (ko) | 2018-12-07 |
| JP7278776B2 (ja) | 2023-05-22 |
| US10314843B2 (en) | 2019-06-11 |
| EP3443351A1 (en) | 2019-02-20 |
| EP3443351A4 (en) | 2019-12-18 |
| IL262325A (en) | 2018-11-29 |
| JP2019511553A (ja) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012146A (es) | Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. | |
| MX2023000549A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| BR112017018234A2 (pt) | inibidores de pd-1 / pd-l1 para o tratamento de câncer | |
| BR112018073328A2 (pt) | combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade | |
| AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
| CL2018002372A1 (es) | Composiciones y métodos para tratar anemia (divisional solicitud 201503602) | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
| MX385315B (es) | Composiciones y metodos para inhibir actividad de arginasa. | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| MX359227B (es) | Tratamiento de cáncer con inhibidores de tor cinasa. | |
| DOP2019000019A (es) | Metodos para tratar el cancer de prostata | |
| EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
| NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
| MX2018014938A (es) | Combinaciones farmaceuticas para el tratamiento del cancer. | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |